(S)-JQ-35 is primarily utilized in research and development within the field of oncology. It serves as a potent and selective inhibitor of BET (bromodomain and extra-terminal) proteins, which play a critical role in regulating gene expression. By inhibiting these proteins, (S)-JQ-35 disrupts the transcription of oncogenes, making it a valuable tool in the study of cancer biology and potential therapeutic strategies. Its application extends to preclinical studies where it is used to investigate the mechanisms of BET protein inhibition and its effects on tumor growth and progression. Additionally, (S)-JQ-35 is employed in the development of targeted cancer therapies, particularly for cancers that are driven by aberrant gene expression. Researchers also explore its potential in combination therapies to enhance the efficacy of existing cancer treatments.